Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25539730

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2015 Apr 11
First author
Behringer K

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2015 Apr 11;385(9976):1371-3. doi: 10.1016/S0140-6736(14)61701-3.
    note
    Source null
    related pmid
    25539731
    relationship
    Comment in
  2. citation
    Lancet. 2015 Apr 11;385(9976):1396. doi: 10.1016/S0140-6736(15)60720-6.
    note
    Source null
    related pmid
    25890421
    relationship
    Erratum in

Authors and identifiers

  1. name
    Behringer K
    type
    Author
  2. name
    Goergen H
    type
    Author
  3. name
    Hitz F
    type
    Author
  4. name
    Zijlstra JM
    type
    Author
  5. name
    Greil R
    type
    Author
  6. name
    Markova J
    type
    Author
  7. name
    Sasse S
    type
    Author
  8. name
    Fuchs M
    type
    Author
  9. name
    Topp MS
    type
    Author
  10. name
    Soekler M
    type
    Author
  11. name
    Mathas S
    type
    Author
  12. name
    Meissner J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Behringer K
    type
    Author
  2. name
    Goergen H
    type
    Author
  3. name
    Hitz F
    type
    Author
  4. name
    Zijlstra JM
    type
    Author
  5. name
    Greil R
    type
    Author
  6. name
    Markova J
    type
    Author
  7. name
    Sasse S
    type
    Author
  8. name
    Fuchs M
    type
    Author
  9. name
    Topp MS
    type
    Author
  10. name
    Soekler M
    type
    Author
  11. name
    Mathas S
    type
    Author
  12. name
    Meissner J
    type
    Author
bibliography ids
  1. nci-bib-884d9222e7fa946b02cd851c
book metadata
content sha256
69c3653f9f1233f0d9e6759db9089e0dadbf7f721e7dfff85a68122a0e9a44e4
document type
citation
dois
  1. 10.1016/S0140-6736(14)61469-0
electronic publication date
display
2014 Dec 22
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:25539730
immutable id
pubmed:25539730@69c3653f9f1233f0d9e6759db9089e0dadbf7f721e7dfff85a68122a0e9a44e4
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9976
name
Lancet (London, England)
nlm unique id
2985213R
pages
1418-27
volume
385
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2015 Apr 11;385(9976):1371-3. doi: 10.1016/S0140-6736(14)61701-3.
    note
    Source null
    related pmid
    25539731
    relationship
    Comment in
  2. citation
    Lancet. 2015 Apr 11;385(9976):1396. doi: 10.1016/S0140-6736(15)60720-6.
    note
    Source null
    related pmid
    25890421
    relationship
    Erratum in
outcomes validated
false
pmid
25539730
provenance
batch id
863b068fe5a07222af6a
provider
NCBI PubMed ESummary
record sha256
6d0fc829bde772b5c97ddbd0e655745f7c4c3fe75fdb7107babe3a175fcc343d
response sha256
80b1cc99e93fcfceb3e1b12ea433c615b032a2db13a615db7a6e9382c17c5034
retrieved at
2026-09-09T23:47:07.648963+00:00
publication date
display
2015 Apr 11
precision
day
year
2015
publication types
  1. Comparative Study
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25539730/
title
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Preserved source evidence · Not medical advice